A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic miceAlexandre Quilbé(Inserm), Nadira Delhem(Inserm)Frontiers in ImmunologyNovember 30, 202310.3389/fimmu.2023.1267279Cited by 7SaveCiteExport RISWatch citationsRelated PapersThe Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes|Cancers|2018|22